Costing about $4 per 10-day course, fluvoxamine could be a game-changer for poorer countries with low vaccination rates and lacking access to more advanced COVID-19 therapies, he added.
Fluvoxamine has been used since the 1990s for various conditions and its safety profile is well-known. It was identified early in the pandemic for its potential to reduce the cytokine storm in COVID-19 patients.